Institute for Cancer Genetics and Informatics - ICGI

Vi takker for anerkjennelsen - og for viktig støtte til forskningen vår 🥰

For 12 år siden i dag lanserte vi Kreftlex. Vi er så stolte over at det digitale oppslagsverket er slik en verdifull kilde til kvalitetssikret informasjon for kreftpasienter og deres pårørende.

𝐈 𝐝𝐚𝐠, 𝟎𝟒. 𝐟𝐞𝐛𝐫𝐮𝐚𝐫 𝐞𝐫 𝐝𝐞𝐭 𝐕𝐞𝐫𝐝𝐞𝐧𝐬 𝐤𝐫𝐞𝐟𝐭𝐝𝐚𝐠 , 𝐨𝐠 𝐯𝐢 𝐟𝐞𝐢𝐫𝐞𝐫 𝐨𝐠𝐬𝐚̊ 𝐚𝐭 𝐊𝐫𝐞𝐟𝐭𝐥𝐞𝐱 𝐟𝐲𝐥𝐥𝐞𝐫 𝟏𝟐 𝐚̊𝐫! 🥳
I år løfter Kreftforeningen frem prehabilitering som et fokusområde innen kreftbehandling, altså det å forberede seg før kreftbehandlingen starter. Ved å styrke både kropp og sinn kan behandlingen bli litt lettere å stå i. 🥰

Takk til alle dere som bruker og støtter Kreftlex. Sammen sprer vi kunnskap og trygghet! 🫶
https://kreftlex.no/

Våre kolleger har representert instituttet på onkologisk forum i Trondheim!

Vår forskningsleder Andreas Kleppe er tildelt midler for banebrytende forskning på digitalpatologi og kunstig intelligens. Les artikkel på Oslo universitetssykehus' nettsider:
https://www.oslo-universitetssykehus.no/avdelinger/kreftklinikken/institutt-for-kreftgenetikk-og-informatikk/FRIPRO-midler-til-Andreas-Kleppe/

⏰ This post is a bit late – but our team certainly wasn’t during Holmenkollstafetten this year! 😄

The Institute for Cancer Genetics and Informatics (with a boost of running power from DoMore Diagnostics💪) joined a whole load of teams from Oslo universitetssykehus, running faster than ever before! Thanks to a wisely chosen t-shirt colour and nearly flawless handovers, we pulled off the near-impossible: no one got lost in a crowd of 75,000 people!

All sections at ICGI were represented, and the atmosphere in the city of Oslo was electric. We almost earned a medal – but a heroic last-minute substitution (a woman stepping in for an ill male runner) meant we couldn’t change our race category, so the tougher time requirement was just out of reach. Still, we finished strong, and the team spirit was unbeatable 💃🏃‍♂️

Rumour has it several colleagues are already eager to join next year’s team – so selection and training for 2026 starts now! Time to lace up!

Kreftlex

Great days here in Rome attending the European Society of Gynaecological Oncology - ESGO and ENITEC meetings. Today Dr. Manohar Pradhan presented our research on Prognostic value of different stages of maturation of tertiary lymphoid structures in molecular subgroups in endometrial carcinoma.

Kildal, Askautrud, Lindemann, , , Oslo universitetssykehus

We are honoured to be part of the NEXTMAP project, recently mentioned in Dagens Medisin. Alongside our esteemed partners, ICGI is dedicated to harnessing AI for cancer prevention and treatment.

Hvordan bli verdensledende innen KI og kreft Norge kan redde millioner av liv og setter Europa i front i kampen mot kreft – hvis vi våkner opp av dvalen i tide.

Takk til Histoteknikerforeningen for flott seminar! Interessante foredrag, velorganisert, nyttig erfaringsutveksling og god mat. Alltid gøy med ny innsikt og gode kolleger.

Patients with advanced/recurrent endometrial carcinoma have poor outcomes. Molecular classification can help in prognostication, even for advanced stages.

The current implementation of immunotherapy in addition to chemotherapy is expected to significantly improve outcomes for these patients, particularly those with mismatch repair deficient advanced/recurrent disease.

See our article in the International Journal of Gynecological Cancer for details: https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(24)22171-X/fulltext

Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer

This article published in the journal Gynecologic Oncology last Friday, sheds new light on the role of L1CAM, in high-risk endometrial cancer. The article is the result of a collaboration between the Institute of Cancer Genetics and Informatics and the Department of Surgical Oncology, Section for Gynecological Oncology, at Oslo University Hospital, supported by a grant from the Norwegian Cancer Society.

Highlights
• Clearer role of molecular classification and L1CAM in high-risk endometrial cancer.
•ProMisE independently predicted time to recurrence, not cancer-specific survival.
•Patients with POLE mutated tumors had an excellent prognosis.
•L1CAM overexpression was a strong, independent marker for recurrence and survival.
•L1CAM overexpression was related to distant recurrences for the p53 and NSMP group.

Since L1CAM is an additional adverse factor in the p53 abnormal and NSMP groups. These groups need special attention in studies intensifying adjuvant treatment.

, Oslo universitetssykehus, Kreftforeningen, Gynkreftforeningen, European Society of Gynaecological Oncology - ESGO
Andreas Kleppe, Kristina Lindemann, Wanja Kildal, Kari Anne Tobin, Manohar Pradhan, Ljiljana Vlatkovic, Maria Xepapdakis Isaksen, Håvard E. Danielsen, Hanne Askautrud, Gunnar Kristensen

https://www.gynecologiconcology-online.net/article/S0090-8258(24)01202-2/fulltext

På IKI tar vi vare på hverandre❤️ved blant annet å delta på kurs i praktisk hjerte- lungeredning. Takk til gode (interne) instruktører!🧡💚💜💪

Oslo universitetssykehus